Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab and Balstilimab in MSS Colorectal Cancer with Persistent ctDNA
NCT07227636Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2025
- Primary completion
- Nov 2030
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botensilimab and balstilimab in colorectal cancer (CRC) (3 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Rate of ctDNA clearance at 6 months and Recurrence-free survival at 1 year. Started Nov 2025; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07227636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227636.